🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Intuitive Surgical CFO sells shares worth $101,332

Published 2024-12-02, 01:38 p/m
ISRG
-

SUNNYVALE, Calif.—Samath Jamie, the Chief Financial Officer and Head of Business Technology at Intuitive Surgical Inc . (NASDAQ:ISRG), recently reported stock transactions in a filing with the Securities and Exchange Commission. The transactions come as the medical device maker's stock trades near its 52-week high of $552, having delivered an impressive 60% return year-to-date. On November 29, Jamie sold 188 shares of Intuitive Surgical's common stock at a price of $539.00 per share, totaling $101,332.

Additionally, Jamie exercised stock options to acquire 188 shares at prices ranging from $208.90 to $290.33, with a total transaction value of $46,927. These transactions were conducted under a pre-arranged trading plan in accordance with SEC Rule 10b5-1, set to expire on May 6, 2025. Following these transactions, Jamie holds 8,757 shares of Intuitive Surgical common stock.

In other recent news, Intuitive Surgical has seen a series of upgrades and raised price targets from financial institutions. Morgan Stanley (NYSE:MS) upgraded the company's stock from Equalweight to Overweight, emphasizing the firm's long-term prospects in the healthcare robotics sector, and raised the price target to $650. Similarly, Erste Group upgraded Intuitive Surgical from Hold to Buy, predicting robust financial performance in the upcoming years with double-digit growth rates in sales and profits for 2024 and 2025.

Additionally, Piper Sandler and RBC (TSX:RY) Capital Markets adjusted their price targets following the company's strong earnings report, with Piper Sandler raising its target to $538 and RBC Capital Markets to $555. Mizuho (NYSE:MFG) Securities also increased its price target to $550, maintaining a neutral stance.

These adjustments followed Intuitive Surgical's robust third-quarter results, with revenue reaching $2 billion, marking a 17% year-over-year increase, driven by an 18% rise in DaVinci procedures and strong system placements. The company also raised its full-year 2024 procedure growth forecast to a range of 16% to 17%.

Despite pricing pressures in China, Intuitive Surgical is preparing for a broad launch of DaVinci 5 by mid-2025 and plans to expand the Ion system internationally, especially in China and Europe. These are some of the recent developments for the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.